Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BTLC, Ltd. 〉TLC388

TLC388

TLC388

TLC388 is a first-in-class oncology therapy currently in development for hepatocellular carcinoma and rectal cancer.

Request for Collaboration
Overview
Poor solubility and high toxicity are significant problems with many new promising therapeutic approaches in oncology. By using TLC's lipid-based technology to improve solubility characteristics of a new derivative from a well-known chemotherapeutic drug (camptothecin), we were able to enhance its clinical development potential.  In addition, TLC388 shows improved tolerability when compared to its parent class of chemotherapies.

The improved tolerability of TLC388 provides more flexibility for physicians in clinical settings to different oncology indications, using higher doses when appropriate while avoiding the side effects commonly associated with chemotherapy drugs. TLC388 has been granted orphan drug designation in U.S. and E.U. for the treatment of hepatocellular carcinoma.  It has also been accepted into the “Accelerated Review Process”, also known as “Green Path” program in China.
Application
Hepatocellular carcinoma /rectal cancer
Advantages:
Multi-functional camptothecin derivative
  • Broad usage in Chemotherapy:
  1. TOP1 Inhibition
  2. HIF-1a Inhibition
  3. Sonic Hedgehog inhibitionProprietary polymeric micelle Formulation
 
  • Radiosensitization
  • Proprietary polymeric micelle formulation
People who like this also like
  • Lead discoveryLead discovery
  • TiMAX Dental ServiceTiMAX Dental Service
  • PixoTest technologyPixoTest technology
  • CX-5461: RNA Polymerase I (Pol I) Inhibitor ProgramCX-5461: RNA Polymerase I (Pol I) Inhibitor Program
  • Zelnite®Zelnite®
  • TAT-HOXB4TAT-HOXB4
  • PipelinePipeline
  • SB05SB05
  • Clinical & Regulatory ExpertiseClinical & Regulatory Expertise
  • ORADUR-methylphenidateORADUR-methylphenidate